<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Microbiol</journal-id><journal-title-group><journal-title>BMC Microbiology</journal-title></journal-title-group><issn pub-type="epub">1471-2180</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2180-9-10</article-id><article-id pub-id-type="pmid">19146699</article-id><article-id pub-id-type="doi">10.1186/1471-2180-9-10</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research article</subject></subj-group></article-categories><title-group><article-title>Genetic evaluation of relationship between mutations in <italic>rpoB </italic>and resistance of <italic>Mycobacterium tuberculosis </italic>to rifampin</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Zaczek</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>ania.zaczek@yahoo.pl</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Brzostek</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>abrzostek@cbm.pan.pl</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Augustynowicz-Kopec</surname><given-names>Ewa</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>e.kopec@igichp.edu.pl</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Zwolska</surname><given-names>Zofia</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>z.zwolska@igichp.edu.pl</email></contrib><contrib contrib-type="author" corresp="yes" id="A5"><name><surname>Dziadek</surname><given-names>Jaroslaw</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jdziadek@cbm.pan.pl</email></contrib></contrib-group><aff id="I1"><label>1</label>Institute for Medical Biology, Polish Academy of Sciences, Lodz, Poland</aff><aff id="I2"><label>2</label>Department of Genetics, University of Rzeszow, Rzeszow, Poland</aff><aff id="I3"><label>3</label>Department of Microbiology, National Research Institute of Tuberculosis and Lung Diseases, Warsaw, Poland</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>15</day><month>1</month><year>2009</year></pub-date><volume>9</volume><fpage>10</fpage><lpage>10</lpage><history><date date-type="received"><day>17</day><month>10</month><year>2008</year></date><date date-type="accepted"><day>15</day><month>1</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2009 Zaczek et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Zaczek et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2180/9/10"/><abstract><sec><title>Background</title><p>Rifampin is a first line antituberculosis drug active against bacilli in logarithmic and stationary phase, which interferes with RNA synthesis by binding to bacterial RNA polymerase. Tubercle bacilli achieve resistance to rifampin by accumulation of mutations in a short-81 bp region of the <italic>rpoB </italic>gene. Among many mutations identified in the <italic>rpo</italic>B gene, few were verified by molecular genetic methods as responsible for resistance to rifampin (RMP).</p></sec><sec><title>Results</title><p>In this study eight different mutations identified in an 81 bp section of a "hot spot" region of the <italic>rpo</italic>B gene of RMP resistant <italic>Mycobacterium tuberculosis </italic>clinical strains were evaluated in respect to drug resistance. It was found that: mutations in positions 526 (H/D), 516 (D/V) and 531 (S/L) result in high level resistance to rifampin; mutations in positions 516 (D/Y), 515 (M/I), 510 (Q/H) or a double mutation in codons 512 (S/I) and 516 (D/G) relate to low level of resistance. Gene <italic>rpo</italic>B carrying mutations in codon 513 (Q/L) introduced into an <italic>M. tuberculosis </italic>laboratory strain did not cause resistance to rifampin, however the same gene introduced into two different clinical strains did, with the level of resistance depending on the host strain.</p></sec><sec><title>Conclusion</title><p>Mutations in an 81 bp "hot spot" region of the <italic>rpoB </italic>of <italic>M. tuberculosis </italic>lead to different levels of resistance to rifampin. Some mutations in this "hot spot" region of <italic>rpoB </italic>require a specific genetic background for the host strain to develop resistance to rifampin. Therefore, the identification of such mutations in a clinical <italic>M. tuberculosis </italic>strain is not enough to classify the given strain as resistant to rifampin.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Tuberculosis (TB) is a devastating infectious disease causing high mortality and morbidity worldwide with 8 million new TB cases and 2&#x02013;3 million deaths annually. The situation of TB is made even worse by the rising emergence of drug resistant strains of <italic>Mycobacterium tuberculosis</italic>. Multi-drug resistant TB (MDR-TB) is defined as resistant to at least isoniazid (INH) and rifampin (RMP), the two most active first-line drugs against TB. MDR-TB treatment takes up to 2 years with second line drugs, which are expensive and have side effects. In 2006 US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) drew attention to the emergence of <italic>M. tuberculosis </italic>with extensive drug resistance to second-line antituberculosis drugs (XDR). XDR-TB is resistant to at least INH and RMP among the first-line drugs and to at least one of three injectable second-line anti-tuberculosis drugs used in TB treatment (capreomycin, kanamycin, amikacin) [<xref ref-type="bibr" rid="B1">1</xref>]. Thus, the treatment of such tuberculosis is becoming seriously limited, sometimes returning TB control to the pre-antibiotic era [<xref ref-type="bibr" rid="B1">1</xref>]. Tuberculosis chemotherapy started in 1944, when streptomycin (SM) was administered for the first time to a critically ill TB patient. Later, TB treatment was enriched with paraaminosalicylic acid (PAS-1949), INH (1952), pyrazinamide (PZA-1954), ethambutol (EMB-1962) and RMP (1963). It was identified that monotherapy generates drug-resistant mutants within a few months, endangering the success of antibiotic treatment. This problem was overcome by using combinations of drugs with as many as four drugs recommended nowadays by CDC and WHO [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>The key antituberculosis drug commonly used in the treatment of tuberculosis is RMP. The loss of RMP as an effective drug leads to a need for a longer duration of therapy and often to a lower cure rate [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. Drug resistance in <italic>M. tuberculosis </italic>is caused by mutations of various chromosomal genes, as identified for MDR occurrence due to the sequential accumulation of mutations in different genes that provide resistance to individual drugs. The individual molecular mechanisms of resistance have been identified for all first-line drugs and the majority of second-line drugs [<xref ref-type="bibr" rid="B7">7</xref>]. In <italic>M. tuberculosis</italic>, resistance to RMP results from mutations in the &#x003b2;-subunit of RNA polymerase, which is encoded by the <italic>rpo</italic>B gene [<xref ref-type="bibr" rid="B8">8</xref>]. Approximately 95% of RMP-resistant strains carry mutations within an 81-bp region containing codons 507 through 533 of the <italic>rpoB </italic>gene [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. The single mechanism of resistance and narrow distribution of mutations make <italic>rpoB</italic>-81 bp region very attractive for molecular detection of resistance to RMP [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. However, within several dozen different mutations detected in the <italic>rpoB</italic>-81 bp region of RMP-resistant <italic>M. tuberculosis </italic>strains [for review see [<xref ref-type="bibr" rid="B13">13</xref>]], very few were tested by cloning and complementation assays. Mutated <italic>rpoB </italic>genes (S531L; H526Y; D516V) were introduced into the RMP sensitive <italic>M. tuberculosis </italic>H<sub>37</sub>Rv strain, resulting in acquired drug resistance of the host strain [<xref ref-type="bibr" rid="B14">14</xref>]. These authors observed that the level of acquired resistance was higher for mutants carrying mutations in codons 531 and 526 compared to mutation in codon 516. In this paper a genetic model was constructed allowing for a relatively simple verification of the relationship between the presence of a given mutation in <italic>rpoB</italic>-81 bp region and the RMP resistance of the host strain carrying such a mutation. Some <italic>rpoB </italic>mutations revealed drug-resistance only in selected <italic>M. tuberculosis </italic>strains suggesting that genetic background of the host is important for the development of resistance to RMP.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Bacterial strains and growth conditions</title><p>The <italic>M. tuberculosis </italic>strains examined for this study were isolated from TB patients in Poland in 2000 during the second national survey of drug resistance [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. Eight clinical strains identified as drug resistant, carrying different mutations in the <italic>rpoB </italic>gene, and two susceptible strains identified as drug sensitive, which did not carry any mutation in <italic>rpoB</italic>, were selected. Moreover, a control laboratory strain <italic>M. tuberculosis </italic>H<sub>37</sub>Ra, was included in this study. Primary isolation, differentiation, and drug susceptibility testing were performed with Lowenstein-Jensen (LJ) medium and the BACTEC 460-TB system (Becton-Dickinson, Sparks, Md.), as reported earlier [<xref ref-type="bibr" rid="B15">15</xref>]. All mycobacterial strains used in this study were cultured in Middlebrook 7H9 broth supplemented with OADC (albumin-dextrose-sodium chloride) and with kanamycin (25 &#x003bc;g/ml), or hygromycin (10 &#x003bc;g/ml), when required. Mycobacterial transformants were selected on Middlebrook 7H10 agar plates enriched with OADC containing kanamycin (Km) or hygromycin (Hyg).</p></sec><sec><title>Gene cloning strategies</title><p>Standard molecular biology protocols were used for all cloning procedures [<xref ref-type="bibr" rid="B16">16</xref>]. All PCR products were obtained using thermostable ExTaq polymerase (Takara) and cloned initially into pGemT vector (Promega), sequenced, and then released by digestion with appropriate restriction enzymes before cloning into the final vectors. Some restriction enzymes recognition sites were incorporated into the sequence of primers. The primers and plasmids used in this work are listed in Table <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>, respectively. To engineer various <italic>rpoB </italic>genes of <italic>M. tuberculosis </italic>controlled by a natural promoter, a basal pRpoZero vector was constructed (Fig. <xref ref-type="fig" rid="F1">1</xref>). The vector contained the 5' end of <italic>rpoB </italic>until a natural <italic>Bst</italic>EII restriction enzyme recognition site (681 plus 950 bp of upstream region) which was connected to the 3' fragment of the gene starting with a natural <italic>Bst</italic>EII restriction enzyme recognition site (1122 plus 218 bp of downstream region). The resultant construct was used for cloning of the inner <italic>Bst</italic>EII-<italic>Bst</italic>EII fragment (1716 bp) of <italic>rpoB </italic>genes from various <italic>M. tuberculosis </italic>clinical strains resistant to RMP. The correct orientation of cloned <italic>Bst</italic>EII fragments was verified by digestion with <italic>PvuII </italic>endonuclease. Next, the cloned genes controlled by their natural promoter, carrying given mutations or wild type sequence in the hot spot region were relocated into the pMV306 integration vector. The resultant constructs (pMRP1-9) were electrotransformed into RMP susceptible strains, and the integration of DNA was monitored by Km selection and verified by PCR. Alternatively, the investigated <italic>rpoB </italic>genes were relocated without putative promoter sequence into pMV306P<sub><italic>hsp </italic></sub>integration vector under control of strong promoter (P<sub><italic>hsp</italic>65</sub>). The resultant constructs (pMHRP1-9) were electrotransformed into RMP susceptible strains, and the integration of DNA was monitored by Hyg selection and verified by PCR.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Construction strategy of integration (pMRP1-9; pMHRP1-9) and self-replicating (pMERP1-9) plasmids carrying wild type and mutated <italic>rpoB </italic>genes under control of own (pMRP1-9) and heat shock (pMHRP1-9; pMERP1-9) promoter</bold>. Description in the text.</p></caption><graphic xlink:href="1471-2180-9-10-1"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Primer sequences used for PCR amplification</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Amplified region</th><th align="left">Primer</th><th align="left">Sequence</th><th align="center">Product size (bp)</th></tr></thead><tbody><tr><td align="left">promoter region (950 bp) and 5' part of <italic>rpoB </italic>gene (721 bp)</td><td align="left">P-rpo-s</td><td align="left">5'-tctagacgagagcggcggtgcaatc</td><td align="center">1671</td></tr><tr><td/><td align="left">P-rpo-r</td><td align="left">5'-gctcgctggtccagcccagc</td><td/></tr><tr><td align="left">3' part of <italic>rpoB </italic>gene (1258 bp) and downstream region (218 bp)</td><td align="left">3'rpo-s</td><td align="left">5'-cgacaccaagctgggtgcgg</td><td align="center">1476</td></tr><tr><td/><td align="left">3'rpo-r</td><td align="left">5'-aagcttccagtcgcgagtcggcccg</td><td/></tr><tr><td align="left"><italic>Bst</italic>EII fragment of <italic>rpoB </italic>gene including 81-bp hot spot region</td><td align="left">bst-s</td><td align="left">5'-cgcgacaccgtcggcgtgcg</td><td align="center">1852</td></tr><tr><td/><td align="left">bst-r</td><td align="left">5'-aagtgtcgcgcacctcgcgggc</td><td/></tr><tr><td align="left">pMV306 (221 bp) and insert DNA cloned in MCS of this vector</td><td align="left">MV-r</td><td align="left">5'-aaggcccagtctttcgactgagc</td><td align="center">221 + insert</td></tr><tr><td/><td align="left">MV-s</td><td align="left">5'-gtggataaccgtattaccgcc</td><td align="center">DNA</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Plasmids used in this study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Plasmid</th><th align="left">Description</th><th align="left">Source</th></tr></thead><tbody><tr><td align="left" colspan="3"><bold>Cloning vectors</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td align="left">pGemTEasy</td><td align="left">T/A cloning</td><td align="left">Promega</td></tr><tr><td align="left">pMV306H</td><td align="left">mycobacterial integrating vector, Hyg<sup>R</sup></td><td align="left">Med-Immune Inc.</td></tr><tr><td align="left">pMV306K</td><td align="left">mycobacterial integrating vector, Kan<sup>R</sup></td><td align="left">Med-Immune Inc.</td></tr><tr><td align="left">pMV261</td><td align="left">mycobacterial <italic>Escherichia coli </italic>shuttle vector, carrying heat shock (P<sub><italic>hsp</italic>65</sub>) promoter, Km<sup>R</sup></td><td align="left">Med-Immune Inc.</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td align="left" colspan="3"><bold>RpoB expression vectors</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td align="left">pMRP1</td><td align="left">wild type <italic>rpoB </italic>of <italic>M. tuberculosis </italic>H<sub>37</sub>Ra controlled by natural promoter <italic>P</italic><sub><italic>rpoB </italic></sub>cloned in integration vector pMV306K, Kan<sup>R</sup></td><td align="left">This study</td></tr><tr><td align="left">pMRP2-9</td><td align="left">mutated <italic>rpoB </italic>of <italic>M. tuberculosis </italic>clinical strains controlled by natural promoter <italic>P</italic><sub><italic>rpoB </italic></sub>cloned in integration vector pMV306K; 2-represents H526D; 3-D516V; 4-Q510H/D516Y; 5-S512I/D516G; 6-Q513L; 7-M515I/D516Y; 8-D516Y; 9-S531L, respectively, Kan<sup>R</sup></td><td align="left">This study</td></tr><tr><td align="left">pMERP1</td><td align="left">wild type <italic>rpoB </italic>of <italic>M. tuberculosis </italic>H<sub>37</sub>Ra controlled by heat shock promoter P<sub><italic>hsp</italic>65 </sub>in pMV261, Kan<sup>R</sup></td><td align="left">This study</td></tr><tr><td align="left">pMERP2-9</td><td align="left">mutated <italic>rpoB </italic>of <italic>M. tuberculosis </italic>clinical strains controlled by heat shock promoter P<sub><italic>hsp</italic>65 </sub>in pMV261, 2-represents H526D; 3-D516V; 4-Q510H/D516Y; 5-S512I/D516G; 6-Q513L; 7-M515I/D516Y; 8-D516Y; 9-S531L, respectively, Kan<sup>R</sup></td><td align="left">This study</td></tr><tr><td align="left">pMHRP1</td><td align="left">wild type <italic>rpoB </italic>of <italic>M. tuberculosis </italic>H<sub>37</sub>Ra controlled by heat shock promoter P<sub><italic>hsp</italic>65 </sub>in pMV306, Hyg<sup>R</sup></td><td align="left">This study</td></tr><tr><td align="left">pMHRP2-9</td><td align="left">mutated <italic>rpoB </italic>of <italic>M. tuberculosis </italic>clinical strains controlled by heat shock promoter P<sub><italic>hsp</italic>65 </sub>in pMV306, '2-represents H526D; 3-D516V; 4-Q510H/D516Y; 5-S512I/D516G; 6-Q513L; 7-M515I/D516Y; 8-D516Y; 9-S531L, respectively, Hyg<sup>R</sup></td><td align="left">This study</td></tr></tbody></table></table-wrap></sec><sec><title>Susceptibility testing</title><p>Susceptibility testing was conducted using the proportion method on Youmans' liquid medium supplemented with 10% OADC with seven concentrations of RMP (50, 25, 12.5, 6.2, 1.5, 0.75, 0.37 &#x003bc;g/ml). The growth was determined after 21 days of incubation. The results were verified by Alamar Blue Assay [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B19">19</xref>] and by plating bacteria on Middlebrook 7H10 supplemented with OADC and various concentrations of RMP.</p></sec></sec><sec><title>Results</title><sec><title>The level of RMP resistance depends on the site and kind of substitution identified in the rpoB gene</title><p>The epidemiological studies carried out in many clinical laboratories worldwide have revealed several dozen mutations present in the <italic>rpoB </italic>gene of RMP resistant <italic>M. tuberculosis </italic>strains [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B23">23</xref>]. According to our knowledge, only three specific mutations of <italic>rpoB </italic>have been verified so far by molecular cloning techniques [<xref ref-type="bibr" rid="B14">14</xref>]. The complementation of RMP sensitive <italic>M. tuberculosis </italic>strain with <italic>rpoB </italic>gene carrying given mutation is not simply due to the gene length (3519 bp). One step amplification of gene together with its putative promoter based on <italic>M. tuberculosis </italic>genomic DNA as a template and its cloning is rather tough for investigators. To avoid this problem we have engineered pRpoZero vector carrying a 950 bp putative promoter region followed by 5'(721 bp) and 3' (1258 bp) <italic>rpoB </italic>gene fragments of an RMP-sensitive <italic>M. tuberculosis </italic>H<sub>37</sub>Ra strain (Fig. <xref ref-type="fig" rid="F1">1</xref>). The missing inner part of the <italic>rpoB </italic>gene flanked with natural <italic>Bst</italic>EII restriction sites contains an 81-bp mutable region. The <italic>Bst</italic>EII fragment (1716 bp) of <italic>rpoB </italic>gene can be easily amplified based on genomic DNA isolated from investigated <italic>M. tuberculosis </italic>RMP-resistant strains and cloned in frame to complete the <italic>rpoB </italic>gene in the pRpoZero system.</p><p>In this study we have selected eight <italic>M. tuberculosis </italic>RMP-resistant clinical strains carrying different mutations in <italic>rpoB </italic>gene [<xref ref-type="bibr" rid="B12">12</xref>] (Table <xref ref-type="table" rid="T3">3</xref>). The PCR generated <italic>Bst</italic>EII inner fragments of the <italic>rpoB </italic>gene were verified by sequencing and were cloned into the pRpoZero vector. The correct orientation of insert was confirmed by <italic>Pvu</italic>II restriction analysis. Subsequently, the constructed genes, together with the putative promoter region, were relocated into the pMV306 integration vector using <italic>Xba</italic>I and <italic>Hind</italic>III restriction enzymes. The resultant constructs carrying wild type or mutated <italic>rpoB </italic>genes under control of a natural promoter, were electroporated into an RMP-sensitive <italic>M. tuberculosis </italic>H<sub>37</sub>Ra host. The integration of plasmid DNA into the <italic>attB </italic>site of chromosomal DNA was verified by PCR using MVs and MVr primers.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Rifampin resistance of clinical and control <italic>M. tuberculosis </italic>strains</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center"><italic>M. tuberculosis </italic>clinical strains</th><th align="center">mutated amino acid of RpoB</th><th align="center">MIC of rifampin (&#x003bc;g/ml)</th></tr></thead><tbody><tr><td align="center">Mt.2</td><td align="center">H526D</td><td align="center">25</td></tr><tr><td align="center">Mt.3</td><td align="center">D516V</td><td align="center">25</td></tr><tr><td align="center">Mt.4</td><td align="center">Q510H; D516Y</td><td align="center">25</td></tr><tr><td align="center">Mt.5</td><td align="center">S512I; D516G</td><td align="center">12,5</td></tr><tr><td align="center">Mt.6</td><td align="center">Q513L</td><td align="center">50</td></tr><tr><td align="center">Mt.7</td><td align="center">M515I; D516Y</td><td align="center">25</td></tr><tr><td align="center">Mt.8</td><td align="center">D516Y</td><td align="center">12,5</td></tr><tr><td align="center">Mt.9</td><td align="center">S531L</td><td align="center">25</td></tr><tr><td align="center">KL1936</td><td align="center">-</td><td align="center">1,5</td></tr><tr><td align="center">KL463</td><td align="center">-</td><td align="center">1,5</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td align="center"><bold>control strain</bold></td><td/><td/></tr><tr><td colspan="3"><hr/></td></tr><tr><td align="center">H<sub>37</sub>Ra</td><td align="center">-</td><td align="center">1,5</td></tr></tbody></table></table-wrap><p>The wild type clinical strains and engineered <italic>M. tuberculosis </italic>H<sub>37</sub>Ra mutants were subjected to RMP-resistance analysis using the proportional method. Each strain was encoded by number and analyzed at least three times by standard procedure at the National Reference Center for Mycobacteria in Poland. The results obtained by the proportional method were verified using Alamar Blue Assay and by plating bacteria on Middebrook 7H10 supplemented with OADC and various concentrations of RMP (data not shown). The results obtained for clinical strains and engineered mutants are summarized in Table <xref ref-type="table" rid="T3">3</xref> and <xref ref-type="table" rid="T4">4</xref>, respectively. Only three out of eight analyzed mutations (H526D; D516V; S531L) revealed the same level of RMP-resistance in clinical strains and engineered H<sub>37</sub>Ra mutants. Introduction of other mutations identified in RMP-resistant <italic>M. tuberculosis </italic>clinical strains into the H<sub>37</sub>Ra host did not result in resistance to RMP or the level of MIC was very low in comparison with clinical strains. Mutation of codon 516 substituting D with V resulted in a high level of RMP resistance. This effect was not observed when D was substituted with Y or G, even when an extra mutation was present in codon 510, 512 or 515.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Rifampin resistance of <italic>M. tuberculosis </italic>recombinant clones</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center" colspan="4">MIC of rifampin (&#x003bc;g/ml) of <italic>M. tuberculosis </italic>recombinant clones carrying mutated <italic>rpoB </italic>gene controlled by:</th></tr><tr><th align="center">mutated amino acid of RpoB</th><th align="center" colspan="3"><italic>PrpoB</italic></th><th align="center"><italic>Phsp65</italic></th></tr><tr><th/><th colspan="4"><hr/></th></tr><tr><th/><th align="center">H<sub>37</sub>Ra</th><th align="center">KL1936</th><th align="center">KL463</th><th align="center">H37Ra</th></tr></thead><tbody><tr><td align="center">H526D</td><td align="center">50</td><td align="center">50</td><td align="center">50</td><td align="center">50</td></tr><tr><td align="center">D516V</td><td align="center">25</td><td align="center">25</td><td align="center">25</td><td align="center">25</td></tr><tr><td align="center">Q510H; D516Y</td><td align="center">1,5</td><td align="center">6,2</td><td align="center">6,2</td><td align="center">6,2</td></tr><tr><td align="center">S512I; D516G</td><td align="center">6,2</td><td align="center">6,2</td><td align="center">6,2</td><td align="center">6,2</td></tr><tr><td align="center">Q513L</td><td align="center">6,2</td><td align="center">12,5</td><td align="center">50</td><td align="center">6,2</td></tr><tr><td align="center">M515I; D516Y</td><td align="center">6,2</td><td align="center">6,2</td><td align="center">6,2</td><td align="center">6,2</td></tr><tr><td align="center">D516Y</td><td align="center">3,1</td><td align="center">6,2</td><td align="center">3,1</td><td align="center">6,2</td></tr><tr><td align="center">S531L</td><td align="center">50</td><td align="center">50</td><td align="center">50</td><td align="center">50</td></tr></tbody></table></table-wrap></sec><sec><title>Some rpoB mutations are able to cause RMP resistance only in a particular <italic>M. tuberculosis </italic>host</title><p>The observed different levels of resistance of <italic>M. tuberculosis </italic>clinical strains and H<sub>37</sub>Ra strain carrying <italic>rpoB </italic>genes mutated at the same positions lead to the conclusion that some mutations in the <italic>rpoB </italic>gene can reveal drug-resistant phenotype only in a specific genetic background of the host. To verify this hypothesis integration vectors carrying mutated <italic>rpoB </italic>genes under natural promoters were introduced by electroporation into two <italic>M. tuberculosis </italic>clinical strains (KL463; KL1936) sensitive to RMP. The selected transformants were verified by PCR amplification as described above. The resultant clinical strains carrying mutated <italic>rpoB </italic>genes were subjected to RMP resistance analysis by the proportional method. The results obtained were compared to the RMP-resistance of clinical strains carrying the same mutations and to the H<sub>37</sub>Ra recombinants described above (Table <xref ref-type="table" rid="T4">4</xref>). The mutated <italic>rpoB </italic>genes generating high RMP-resistance level in <italic>M. tuberculosis </italic>H<sub>37</sub>Ra (H526D; D516V; S531L) were also responsible for high level of resistance of both clinical strains when introduced into their chromosomal DNA. On the other hand, mutation Q513L identified in an <italic>M. tuberculosis </italic>strain with resistance to a high level of RMP (MIC up to 50 &#x003bc;g/ml) which did not cause significant resistance of <italic>M. tuberculosis </italic>H<sub>37</sub>Ra (MIC up to 6.2 &#x003bc;g/ml), was responsible for RMP-resistance of KL463 and KL1936 strains at the level depending on the host (up to 12.5 and 50 &#x003bc;g/ml, respectively). The double mutation of <italic>rpoB </italic>in positions 510 (Q/H) and 516 (D/Y) identified in a highly resistant <italic>M. tuberculosis </italic>strain (MIC 25 &#x003bc;g/ml) which did not reveal resistance in H<sub>37</sub>Ra (MIC 1.5 &#x003bc;g/ml) was responsible for low level of resistance of both clinical tubercle bacilli hosts (MIC 6.2 &#x003bc;g/ml).</p></sec><sec><title>The overproduction of mutated RpoB does not cause high level of resistance to RMP</title><p>We could not exclude that the different resistance of <italic>M. tuberculosis </italic>hosts carrying identical mutations in <italic>rpoB </italic>depends on different expression of RpoB controlled by unknown regulatory proteins. For example, the raised expression of target molecule (InhA) due to accumulations of mutations in promoter region is one of the known mechanisms of resistance to INH. As questions arose as to whether expression of mutated <italic>rpoB </italic>genes under control of the heat shock promoter (<italic>P</italic><sub><italic>hsp</italic>60</sub>) resulted in increased resistance of <italic>M. tuberculosis </italic>to RMP, the wild type <italic>rpoB </italic>and its mutated copies were cloned under control of the heat shock promoter as described in Methods. Although we did not have antibodies to test the level of expression for RpoB, the expression system is known to be very efficient [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. The self-replicating constructs (pMERP1-9, Fig. <xref ref-type="fig" rid="F1">1</xref>) appeared to be very unstable when introduced into <italic>M. tuberculosis </italic>host (data not shown). Therefore the vectors (pMHRP1-9), which are able to integrate into <italic>attB </italic>site of mycobacterial chromosomal DNA, carrying wild type and mutated <italic>rpoB </italic>under <italic>P</italic><sub><italic>hsp</italic>60 </sub>promoter were constructed and electroporated into <italic>M. tuberculosis </italic>H<sub>37</sub>Ra. The presence of the relevant DNA introduced into the <italic>attB </italic>site of chromosomal DNA was verified by PCR amplification. The resultant recombinant strains were subjected to RMP resistance analysis by the proportional method. The results of RMP-MIC analysis obtained for strains carrying mutated <italic>rpoB </italic>genes under control of the strong <italic>P</italic><sub><italic>hsp</italic>60 </sub>promoter were similar to strains carrying the same <italic>rpoB </italic>genes under control of their natural promoter (Table <xref ref-type="table" rid="T4">4</xref>). These observations suggest that the RMP-resistance of <italic>M. tuberculosis </italic>strains carrying <italic>rpoB </italic>mutated genes was not dependent on the <italic>rpoB </italic>expression level but resulted from the host genetic background that influence the drug-resistance phenotype.</p></sec></sec><sec><title>Discussion</title><p>All bacteria achieve resistance to RMP by mutations in a defined region of the RNA polymerase subunit &#x003b2;. In <italic>M. tuberculosis</italic>, approximately 95% of RMP resistant clinical isolates carry a mutation in the <italic>rpoB </italic>gene [<xref ref-type="bibr" rid="B8">8</xref>]. On the other hand, many isolates from <italic>M. avium </italic>and <italic>M. intracellulare </italic>present a natural resistance to RMP as a result of an efficient permeability and exclusion barrier [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. Mutations in <italic>rpoB </italic>generally result in high level resistance to RMP. However, specific mutations in codons 511, 516, 518 and 522 can result in a lower resistance to RMP [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. The role of some <italic>rpoB </italic>mutations (H526Y, S531L, D516V) in causing resistance was confirmed by genetic transformation experiments [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. Several dozen other mutations identified in the <italic>rpoB </italic>gene of RMP-resistant <italic>M. tuberculosis </italic>clinical isolates have never been confirmed by genetic cloning [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B35">35</xref>]. Nowadays, when many genetic techniques are well developed, the knowledge about mutations connected to RMP-resistance is becoming used in the rapid identification of drug resistance [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. However, the utility of these techniques depends on the precise information about the role of any given mutation in RMP resistance.</p><p>In this study we have engineered a genetic system which is helpful in the verification of the relationship between the presence of a given mutation in <italic>rpoB </italic>and RMP resistance. We have found that <italic>rpoB </italic>gene carrying either D516V or S531L mutation causes resistance to RMP when introduced into the <italic>M. tuberculosis </italic>hosts what was in agreement with previous investigations [<xref ref-type="bibr" rid="B14">14</xref>]. On the other hand, when mutated <italic>rpoB </italic>was introduced into drug sensitive <italic>M. tuberculosis </italic>laboratory or clinical strains, the other substitutions in position 516 (D/Y; D/G), even when supported with Q510H, M515I or S512I identified in RMP-resistant <italic>M. tuberculosis </italic>clinical strains, did not result in a significant increase of RMP-resistance. Other authors previously reported the identification of D516Y substitutions of <italic>rpoB </italic>in <italic>M. tuberculosis </italic>resistance to a high level of RMP [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B38">38</xref>], low level of RMP [<xref ref-type="bibr" rid="B14">14</xref>] and in strains sensitive to RMP [<xref ref-type="bibr" rid="B39">39</xref>]. Taken together, this suggests that D516Y/G substitutions in <italic>rpoB </italic>are not sufficient to result in RMP-resistance of <italic>M. tuberculosis</italic>. The substitutions in codon 526 (H/Y, D, R, L, P) were usually identified in <italic>M. tuberculosis </italic>clinical isolates highly resistant to RMP [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B38">38</xref>]. In this paper we have provided direct evidence that mutation H526D in <italic>rpoB </italic>is responsible for RMP-resistance when introduced into <italic>M. tuberculosis </italic>host. This result is similar to a previous finding verified by genetic transformation of <italic>rpoB </italic>carrying mutation H526Y [<xref ref-type="bibr" rid="B14">14</xref>]. By contrast, the contribution of <italic>rpoB </italic>carrying Q513L mutation to RMP-resistance was not that evident. The insertion of this gene into an <italic>M. tuberculosis </italic>H<sub>37</sub>Ra laboratory strain did not result in a significant level of RMP-resistance, however the insertion of the same gene was responsible for resistance to RMP of two <italic>M. tuberculosis </italic>clinical strains (MIC 12.5 and 50 &#x003bc;g/ml) when used as hosts. As identified in various clinical studies, the level of RMP-resistance of <italic>M. tuberculosis </italic>isolates carrying the Q513L mutation varies from 2 to 200 &#x003bc;g/ml [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B38">38</xref>]. The collected results suggest that <italic>rpoB </italic>carrying Q513L mutation is able to cause resistance to RMP only in selected tubercle bacilli. It is likely that this mutation can result in RMP-resistance in strains with low cell wall permeability since this exclusion barrier is responsible for natural resistance of some MAIC strains [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. We also cannot exclude the possibility that other mechanisms support RMP-resistance of strains carrying Q513L mutation.</p><p>The drug resistance of <italic>M. tuberculosis </italic>can be also connected to the overproduction of a drug target due to accumulation of point mutations in a promoter region [<xref ref-type="bibr" rid="B40">40</xref>-<xref ref-type="bibr" rid="B42">42</xref>]. To test whether overproduction of <italic>rpoB </italic>carrying a given mutation result in higher MIC for RMP compared to a strain expressing the same gene under control of the natural promoter, <italic>rpoB </italic>genes were cloned under control of the <italic>P</italic><sub><italic>hsp </italic></sub>promoter and introduced into <italic>M. tuberculosis </italic>host. The <italic>P</italic><sub><italic>hsp </italic></sub>promoter, commonly used in genetics studies of mycobacteria controlling the <italic>groEL </italic>gene (Rv0440) in <italic>M. tuberculosis</italic>, has already been reported as highly active in mycobacterial cells growing <italic>in vitro </italic>[<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. A recent microarray study showed that the expression level of <italic>groEL </italic>in <italic>M. tuberculosis </italic>cells growing in log phase is high, but not higher than <italic>rpoB </italic>[<xref ref-type="bibr" rid="B43">43</xref>]. However, the arresting of <italic>M. tuberculosis </italic>growth results in 3.6-fold induction of <italic>groEL </italic>with a decrease of <italic>rpoB </italic>expression in the same conditions [<xref ref-type="bibr" rid="B44">44</xref>]. We have not observed higher RMP resistance when mutated <italic>rpoB </italic>genes were expressed under control of <italic>P</italic><sub><italic>hsp </italic></sub>promoter in comparison to the natural promoter. It is possible that the natural level of RpoB is high enough to saturate RMP (if its concentration in cell is low). On the other hand, the extra expression of <italic>rpoB </italic>cannot help in cells accumulating high RMP level. However, to elucidate this problem an alternative expression system and precise control of protein expression would be required.</p><p>The natural resistance to RMP in some <italic>M. avium </italic>and <italic>M. intracellulare </italic>strains is known to be as a result of an efficient cell wall permeability and exclusion barrier [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>], suggesting that these elements may be also important in <italic>M. tuberculosis</italic>. Changes in cell wall composition could affect permeability [<xref ref-type="bibr" rid="B45">45</xref>] decreasing the intracellular concentration of drug.</p></sec><sec><title>Conclusion</title><p>Among several dozen amino acid substitutions identified in an <italic>rpoB </italic>81-bp region only a few are directly responsible for <italic>M. tuberculosis </italic>resistance to rifampin. Many others require a specific genetic background to develop resistance. Our findings lead to the conclusion that direct, molecular identification of rifampin resistant <italic>M. tuberculosis </italic>clinical isolates is possible only for strains carrying selected mutations in RpoB. The identification of other mutations suggests that investigated strains might be resistant to this drug.</p></sec><sec><title>Authors' contributions</title><p>AZ performed the majority of experiments. AB helped in cloning. EAK and ZZ supervised susceptibility tests. JD conceived and supervised the study and wrote the manuscript. All authors have read and approved the final version of the manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>We acknowledge financial support from grants R130203 and N401 148 31/3268 awarded by the Polish Ministry of Science and Higher Education. We thank Dr. Richard Bowater for critical reading of this manuscript.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Raviglione</surname><given-names>M</given-names></name><article-title>XDR-TB: entering the post-antibiotic era?</article-title><source>Int J Tuberc Lung Dis</source><year>2006</year><volume>10</volume><fpage>1185</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">17131774</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Ormerod</surname><given-names>LP</given-names></name><article-title>Directly observed therapy (DOT) for tuberculosis: why, when, how and if?</article-title><source>Thorax</source><year>1999</year><volume>54 Suppl 2</volume><fpage>S42</fpage><lpage>S45</lpage><pub-id pub-id-type="pmid">10451692</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Mitchison</surname><given-names>DA</given-names></name><name><surname>Nunn</surname><given-names>AJ</given-names></name><article-title>Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis</article-title><source>Am Rev Respir Dis</source><year>1986</year><volume>133</volume><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">2420242</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Espinal</surname><given-names>MA</given-names></name><name><surname>Dye</surname><given-names>C</given-names></name><name><surname>Raviglione</surname><given-names>M</given-names></name><name><surname>Kochi</surname><given-names>A</given-names></name><article-title>Rational 'DOTS plus' for the control of MDR-TB</article-title><source>Int J Tuberc Lung Dis</source><year>1999</year><volume>3</volume><fpage>561</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">10423218</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="book"><collab>World Health Organization</collab><source>Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance (WHO/TB/97.229)</source><year>1997</year><publisher-name>WHO Geneva Switzerland</publisher-name></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="book"><collab>World Health Organization</collab><source>Anti-tuberculosis drug resistance in the world. Third Global Report. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance (WHO/CDC/TB/2004)</source><year>2004</year><publisher-name>WHO Geneva Switzerland</publisher-name></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="book"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Vilcheze</surname><given-names>C</given-names></name><name><surname>Jacobs</surname><given-names>WR</given-names><suffix>Jr</suffix></name><article-title>Mechanisms of drug resistance in <italic>Mycobacterium tuberculosis</italic></article-title><source>Tuberculosis and the Tubercle Bacillus</source><year>2005</year><publisher-name>ASM Press Washington DC</publisher-name><fpage>115</fpage><lpage>140</lpage></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Telenti</surname><given-names>A</given-names></name><name><surname>Imboden</surname><given-names>P</given-names></name><name><surname>Marchesi</surname><given-names>F</given-names></name><name><surname>Lowrie</surname><given-names>D</given-names></name><name><surname>Cole</surname><given-names>S</given-names></name><name><surname>Colston</surname><given-names>MJ</given-names></name><name><surname>Matter</surname><given-names>L</given-names></name><name><surname>Schopfer</surname><given-names>K</given-names></name><name><surname>Bodmer</surname><given-names>T</given-names></name><article-title>Detection of rifampicin-resistance mutations in <italic>Mycobacterium tuberculosis</italic></article-title><source>Lancet</source><year>1993</year><volume>341</volume><fpage>647</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(93)90417-F</pub-id><pub-id pub-id-type="pmid">8095569</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Musser</surname><given-names>JM</given-names></name><article-title>Antimicrobial agent resistance in mycobacteria: molecular genetic insights</article-title><source>Clin Microbiol Rev</source><year>1995</year><volume>8</volume><fpage>496</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">8665467</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Williams</surname><given-names>DL</given-names></name><name><surname>Waguespack</surname><given-names>C</given-names></name><name><surname>Eisenach</surname><given-names>K</given-names></name><name><surname>Crawford</surname><given-names>JT</given-names></name><name><surname>Portaels</surname><given-names>F</given-names></name><name><surname>Salfinger</surname><given-names>M</given-names></name><name><surname>Nolan</surname><given-names>CM</given-names></name><name><surname>Abe</surname><given-names>C</given-names></name><name><surname>Sticht-Groh</surname><given-names>V</given-names></name><name><surname>Gillis</surname><given-names>TP</given-names></name><article-title>Characterization of rifampin-resistance in pathogenic mycobacteria</article-title><source>Antimicrob Agents Chemother</source><year>1994</year><volume>38</volume><fpage>2380</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7840574</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Caoili</surname><given-names>JC</given-names></name><name><surname>Mayorova</surname><given-names>A</given-names></name><name><surname>Sikes</surname><given-names>D</given-names></name><name><surname>Hickman</surname><given-names>L</given-names></name><name><surname>Plikaytis</surname><given-names>BB</given-names></name><name><surname>Shinnick</surname><given-names>TM</given-names></name><article-title>Evaluation of the TB-Biochip oligonucleotide microarray system for rapid detection of rifampin resistance in <italic>Mycobacterium tuberculosis</italic></article-title><source>J Clin Microbiol</source><year>2006</year><volume>44</volume><fpage>2378</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">16825352</pub-id><pub-id pub-id-type="doi">10.1128/JCM.00439-06</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Sajduda</surname><given-names>A</given-names></name><name><surname>Brzostek</surname><given-names>A</given-names></name><name><surname>Pop&#x00142;awska</surname><given-names>M</given-names></name><name><surname>Augustynowicz-Kopec</surname><given-names>E</given-names></name><name><surname>Zwolska</surname><given-names>Z</given-names></name><name><surname>Niemann</surname><given-names>S</given-names></name><name><surname>Dziadek</surname><given-names>J</given-names></name><name><surname>Hillemann</surname><given-names>D</given-names></name><article-title>Molecular characterisation of rifampin-resistant <italic>Mycobacterium tuberculosis </italic>starins isolated in Poland</article-title><source>J Clin Microbiol</source><year>2004</year><volume>42</volume><fpage>2425</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">15184414</pub-id><pub-id pub-id-type="doi">10.1128/JCM.42.6.2425-2431.2004</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="book"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Telenti</surname><given-names>A</given-names></name><article-title>Genetics of drug resistance in <italic>Mycobacterium tuberculosis</italic></article-title><source>Molecular Genetics of Mycobacteria</source><year>2000</year><publisher-name>ASM Press Washington DC</publisher-name><fpage>235</fpage><lpage>253</lpage></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Williams</surname><given-names>DL</given-names></name><name><surname>Spring</surname><given-names>L</given-names></name><name><surname>Collins</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>LP</given-names></name><name><surname>Heifets</surname><given-names>LB</given-names></name><name><surname>Gangadharam</surname><given-names>PR</given-names></name><name><surname>Gillis</surname><given-names>TP</given-names></name><article-title>Contribution of <italic>rpoB </italic>mutations to development of rifamycin cross-resistance in <italic>Mycobacterium tuberculosis</italic></article-title><source>Antimicrob Agents Chemother</source><year>1998</year><volume>42</volume><fpage>1853</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">9661035</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Augustynowicz-Kopec</surname><given-names>E</given-names></name><name><surname>Zwolska</surname><given-names>Z</given-names></name><name><surname>Jaworski</surname><given-names>A</given-names></name><name><surname>Kostrzewa</surname><given-names>E</given-names></name><name><surname>Klatt</surname><given-names>M</given-names></name><article-title>Drug resistant tuberculosis in Poland in 2000: second national survey and comparison with the 1997 survey</article-title><source>Int J Tuberc Lung Dis</source><year>2003</year><volume>7</volume><fpage>1</fpage><lpage>7</lpage></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="book"><name><surname>Sambrook</surname><given-names>J</given-names></name><name><surname>Russel</surname><given-names>DW</given-names></name><source>Molecular Cloning: A Laboratory Manual</source><year>2001</year><publisher-name>Cold Spring Harbor Laboratory Press</publisher-name></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Collins</surname><given-names>LA</given-names></name><name><surname>Franzblau</surname><given-names>SG</given-names></name><article-title>Microplate Alamar Blue Assay versus BACTEC 460 system for hight-throughput screening of compounds against <italic>Mycobacterium tuberculosis </italic>and <italic>Mycobacterium avium</italic></article-title><source>Antimicrob Agents Chemother</source><year>1997</year><volume>41</volume><fpage>1004</fpage><lpage>09</lpage><pub-id pub-id-type="pmid">9145860</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Franzblau</surname><given-names>SG</given-names></name><name><surname>Witzig</surname><given-names>RS</given-names></name><name><surname>McLaughlin</surname><given-names>JC</given-names></name><name><surname>Torres</surname><given-names>P</given-names></name><name><surname>Madico</surname><given-names>G</given-names></name><name><surname>Hernandez</surname><given-names>A</given-names></name><name><surname>Degnan</surname><given-names>MT</given-names></name><name><surname>Cook</surname><given-names>MB</given-names></name><name><surname>Quenzer</surname><given-names>VK</given-names></name><name><surname>Ferguson</surname><given-names>RM</given-names></name><name><surname>Gilman</surname><given-names>RH</given-names></name><article-title>Rapid, low-technology MIC determination with clinical <italic>Mycobacterium tuberculosis </italic>isolates by using the Microplate Alamar Blue Assay</article-title><source>J Clin Microbiol</source><year>1998</year><volume>36</volume><fpage>362</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9466742</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Reis</surname><given-names>RS</given-names></name><name><surname>Neves</surname><given-names>I</given-names><suffix>Jr</suffix></name><name><surname>Lourenco</surname><given-names>SLS</given-names></name><name><surname>Fonseca</surname><given-names>LS</given-names></name><name><surname>Lourenco</surname><given-names>MCS</given-names></name><article-title>Comparison of Flow Cytometric and Alamar Blue Test with the Proportional Method for testing susceptibility of <italic>Mycobacterium tuberculosis </italic>to rifampin and isoniazid</article-title><source>J Clin Microbiol</source><year>2004</year><volume>42</volume><fpage>2247</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">15131202</pub-id><pub-id pub-id-type="doi">10.1128/JCM.42.5.2247-2248.2004</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Taniguchi</surname><given-names>H</given-names></name><name><surname>Aramaki</surname><given-names>H</given-names></name><name><surname>Nikaido</surname><given-names>Y</given-names></name><name><surname>Mizuguchi</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Koga</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name><article-title>Rifampicin resistance and mutation of the <italic>rpoB </italic>gene in <italic>Mycobacterium tuberculosis</italic></article-title><source>FEMS Microbiol Letters</source><year>1996</year><volume>144</volume><fpage>103</fpage><lpage>08</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.1996.tb08515.x</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Koga</surname><given-names>H</given-names></name><name><surname>Ohno</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>K</given-names></name><name><surname>Fukuda</surname><given-names>M</given-names></name><name><surname>Hirakata</surname><given-names>Y</given-names></name><name><surname>Maesaki</surname><given-names>S</given-names></name><name><surname>Tomono</surname><given-names>K</given-names></name><name><surname>Tashiro</surname><given-names>T</given-names></name><name><surname>Kohno</surname><given-names>S</given-names></name><article-title>Detection between antimicrobacterial activities of rifampicin, rifabutin and KRM-1648 and <italic>rpoB </italic>mutations of <italic>Mycobacterium tuberculosis</italic></article-title><source>J Antimicrob Chemother</source><year>1998</year><volume>42</volume><fpage>621</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1093/jac/42.5.621</pub-id><pub-id pub-id-type="pmid">9848446</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Chan</surname><given-names>RCY</given-names></name><name><surname>Hui</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>EWC</given-names></name><name><surname>Au</surname><given-names>TK</given-names></name><name><surname>Chin</surname><given-names>ML</given-names></name><name><surname>Yip</surname><given-names>CK</given-names></name><name><surname>AuYeang</surname><given-names>CKW</given-names></name><name><surname>Yeung</surname><given-names>CYL</given-names></name><name><surname>Kam</surname><given-names>KM</given-names></name><name><surname>Yip</surname><given-names>PCW</given-names></name><name><surname>Cheng</surname><given-names>AFB</given-names></name><article-title>Genetic and phenotypic characterization of drug-resistant <italic>Mycobacterium tuberculosis </italic>isolates in Hong Kong</article-title><source>J Antimicrob Chemother</source><year>2007</year><volume>59</volume><fpage>866</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1093/jac/dkm054</pub-id><pub-id pub-id-type="pmid">17360809</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Huitric</surname><given-names>E</given-names></name><name><surname>Werngren</surname><given-names>J</given-names></name><name><surname>Jureen</surname><given-names>P</given-names></name><name><surname>Hoffner</surname><given-names>S</given-names></name><article-title>Resistance levels and <italic>rpoB </italic>gene mutations among in vitro-selected rifampin-resistant <italic>Mycobacterium tuberculosis </italic>mutants</article-title><source>Antimicrob Agents Chemother</source><year>2006</year><volume>50</volume><fpage>2860</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">16870787</pub-id><pub-id pub-id-type="doi">10.1128/AAC.00303-06</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Dziadek</surname><given-names>J</given-names></name><name><surname>Madiraju</surname><given-names>MVVS</given-names></name><name><surname>Rutherford</surname><given-names>SA</given-names></name><name><surname>Atkinson</surname><given-names>MAL</given-names></name><name><surname>Rajagopalan</surname><given-names>M</given-names></name><article-title>Physiological consequences associated with overproduction of <italic>Mycobacterium tuberculosis </italic>FtsZ in mycobacterial hosts</article-title><source>Microbiology</source><year>2002</year><volume>148</volume><fpage>961</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">11932443</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Brzostek</surname><given-names>A</given-names></name><name><surname>Sliwinski</surname><given-names>T</given-names></name><name><surname>Rumijowska-Galewicz</surname><given-names>A</given-names></name><name><surname>Korycka-Machala</surname><given-names>M</given-names></name><name><surname>Dziadek</surname><given-names>J</given-names></name><article-title>Identification and targeted disruption of the gene encoding the main 3-ketosteroid dehydrogenase in Mycobacterium smegmatis</article-title><source>Microbiology</source><year>2005</year><volume>151</volume><fpage>2393</fpage><lpage>2402</lpage><pub-id pub-id-type="doi">10.1099/mic.0.27953-0</pub-id><pub-id pub-id-type="pmid">16000729</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Hui</surname><given-names>J</given-names></name><name><surname>Gordon</surname><given-names>N</given-names></name><name><surname>Kajioka</surname><given-names>R</given-names></name><article-title>Permeability barrier to rifampin in mycobacteria</article-title><source>Antimicrob Agents Chemother</source><year>1977</year><volume>11</volume><fpage>773</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">879732</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Guerrero</surname><given-names>C</given-names></name><name><surname>Stockman</surname><given-names>L</given-names></name><name><surname>Marchesi</surname><given-names>F</given-names></name><name><surname>Bodmer</surname><given-names>T</given-names></name><name><surname>Roberts</surname><given-names>GD</given-names></name><name><surname>Telenti</surname><given-names>A</given-names></name><article-title>Evaluation of the <italic>rpoB </italic>gene in rifampicin-susceptible and -resistant <italic>Mycobacterium avium </italic>and <italic>Mycobacterium intracellulare</italic></article-title><source>J Antimicrob Chemother</source><year>1994</year><volume>33</volume><fpage>661</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1093/jac/33.3.661-a</pub-id><pub-id pub-id-type="pmid">8040132</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Bodmer</surname><given-names>T</given-names></name><name><surname>Zurcher</surname><given-names>G</given-names></name><name><surname>Imboden</surname><given-names>P</given-names></name><name><surname>Telenti</surname><given-names>A</given-names></name><article-title>Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence <italic>in vitro </italic>activity of rifampin-resistant <italic>Mycobacterium tuberculosis</italic></article-title><source>J Antimicrob Chemother</source><year>1995</year><volume>35</volume><fpage>345</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1093/jac/35.2.345</pub-id><pub-id pub-id-type="pmid">7759399</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Moghazeh</surname><given-names>SL</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Arain</surname><given-names>T</given-names></name><name><surname>Stover</surname><given-names>CK</given-names></name><name><surname>Musser</surname><given-names>JM</given-names></name><name><surname>Kreiswirth</surname><given-names>BN</given-names></name><article-title>Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant <italic>Mycobacterium tuberculosis </italic>isolates with known <italic>rpoB </italic>mutations</article-title><source>Antimicrob Agents Chemother</source><year>1996</year><volume>40</volume><fpage>2655</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">8913484</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>LP</given-names></name><name><surname>Crafword</surname><given-names>JT</given-names></name><name><surname>Shinnick</surname><given-names>TM</given-names></name><article-title>The <italic>rpoB </italic>gene of <italic>Mycobacterium tuberculosis</italic></article-title><source>Antimicrob Agents Chemother</source><year>1994</year><volume>38</volume><fpage>805</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">8031050</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Hillemann</surname><given-names>D</given-names></name><name><surname>Kubica</surname><given-names>T</given-names></name><name><surname>Rusch-Gerdes</surname><given-names>S</given-names></name><name><surname>Niemann</surname><given-names>S</given-names></name><article-title>Disequilibrium in distribution of resistance mutations among <italic>Mycobacterium tuberculosis </italic>Beijing and Non-Beijing strains isolated from patients in Germany</article-title><source>Antimicrob Agents Chemother</source><year>2005</year><volume>49</volume><fpage>1229</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">15728936</pub-id><pub-id pub-id-type="doi">10.1128/AAC.49.3.1229-1231.2005</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name><article-title>Characterization of <italic>rpoB </italic>mutations in rifampicin-resistant <italic>Mycobacterium tuberculosis </italic>isolated in China</article-title><source>Tubecrulosis</source><year>2000</year><volume>82</volume><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1054/tube.2002.0326</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Ozkutuk</surname><given-names>N</given-names></name><name><surname>Gazi</surname><given-names>H</given-names></name><name><surname>Surucuoglu</surname><given-names>S</given-names></name><name><surname>Gunduz</surname><given-names>A</given-names></name><name><surname>Ozbakkaloglu</surname><given-names>B</given-names></name><article-title>Characterization of <italic>rpoB </italic>mutations by Line Probe Assays in rifampicin-resistant <italic>Mycobacterium tuberculosis </italic>clinical isolates from the Aegean region in Turkey</article-title><source>Jpn J Infect Dis</source><year>2007</year><volume>60</volume><fpage>211</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">17642536</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Bostanabad</surname><given-names>S</given-names></name><name><surname>Bahrmand</surname><given-names>A</given-names></name><name><surname>Titov</surname><given-names>LP</given-names></name><name><surname>Taghikhani</surname><given-names>M</given-names></name><article-title>Identification of mutations in the <italic>rpoB </italic>encoding the RNA polymerase beta subunit in rifampicine-resistant <italic>Mycobacterium tuberculosis </italic>strains from Iran</article-title><source>Tuberk Toraks</source><year>2007</year><volume>55</volume><fpage>370</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">18224505</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Brossier</surname><given-names>F</given-names></name><name><surname>Veziris</surname><given-names>N</given-names></name><name><surname>Truffot-Pernot</surname><given-names>C</given-names></name><name><surname>Jarlier</surname><given-names>V</given-names></name><name><surname>Sougakoff</surname><given-names>W</given-names></name><article-title>Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of <italic>Mycobacterium tuberculosis </italic>with low- and high-level resistance</article-title><source>J Clin Microbiol</source><year>2006</year><volume>44</volume><fpage>3659</fpage><lpage>3664</lpage><pub-id pub-id-type="pmid">17021094</pub-id><pub-id pub-id-type="doi">10.1128/JCM.01054-06</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Gryadunov</surname><given-names>D</given-names></name><name><surname>Mikhailovich</surname><given-names>V</given-names></name><name><surname>Lapa</surname><given-names>S</given-names></name><name><surname>Roudinskii</surname><given-names>N</given-names></name><name><surname>Donnikov</surname><given-names>M</given-names></name><name><surname>Pan'kov</surname><given-names>S</given-names></name><name><surname>Markova</surname><given-names>O</given-names></name><name><surname>Kuz'min</surname><given-names>A</given-names></name><name><surname>Chernousova</surname><given-names>L</given-names></name><name><surname>Skotnikova</surname><given-names>O</given-names></name><name><surname>Moroz</surname><given-names>A</given-names></name><name><surname>Zasedatelev</surname><given-names>A</given-names></name><name><surname>Mirzabekov</surname><given-names>A</given-names></name><article-title>Evaluation of hybridisation on oligonucleotide microarrays for analysis of drug-resistant <italic>Mycobacterium tuberculosis</italic></article-title><source>Clin Microbiol Infect</source><year>2005</year><volume>11</volume><fpage>531</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2005.01183.x</pub-id><pub-id pub-id-type="pmid">15966970</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Mikhailovich</surname><given-names>V</given-names></name><name><surname>Lapa</surname><given-names>S</given-names></name><name><surname>Gryadunov</surname><given-names>D</given-names></name><name><surname>Sobolev</surname><given-names>A</given-names></name><name><surname>Strizhkov</surname><given-names>B</given-names></name><name><surname>Chernyh</surname><given-names>N</given-names></name><name><surname>Skotnikova</surname><given-names>O</given-names></name><name><surname>Irtuganova</surname><given-names>O</given-names></name><name><surname>Moroz</surname><given-names>A</given-names></name><name><surname>Litvinov</surname><given-names>V</given-names></name><name><surname>Vladimirskii</surname><given-names>M</given-names></name><name><surname>Perelman</surname><given-names>M</given-names></name><name><surname>Chernousova</surname><given-names>L</given-names></name><name><surname>Erokhin</surname><given-names>V</given-names></name><name><surname>Zasedatelev</surname><given-names>A</given-names></name><name><surname>Mirzabekov</surname><given-names>A</given-names></name><article-title>Identification of rifampin-resistant <italic>Mycobacterium tuberculosis </italic>strains by hybridization, PCR, and ligase detection reaction on oligonucleotide microchips</article-title><source>J Clin Microbiol</source><year>2001</year><volume>39</volume><fpage>2531</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">11427565</pub-id><pub-id pub-id-type="doi">10.1128/JCM.39.7.2531-2540.2001</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Hwang</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><article-title>Characterisation of rifampicin-resistant <italic>Mycobacterium tuberculosis </italic>in Taiwan</article-title><source>J Clin Microbiol</source><year>2003</year><volume>52</volume><fpage>239</fpage><lpage>45</lpage></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Somoskovi</surname><given-names>A</given-names></name><name><surname>Dormandy</surname><given-names>J</given-names></name><name><surname>Mitsani</surname><given-names>D</given-names></name><name><surname>Rivenburg</surname><given-names>J</given-names></name><name><surname>Salfinger</surname><given-names>M</given-names></name><article-title>Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the <italic>Mycobacterium tuberculosis </italic>complex as well as its resistance to isoniazid and rifampin</article-title><source>J Clin Microbiol</source><year>2006</year><volume>44</volume><fpage>4459</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">17035488</pub-id><pub-id pub-id-type="doi">10.1128/JCM.01506-06</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Dubnau</surname><given-names>E</given-names></name><name><surname>Quemard</surname><given-names>A</given-names></name><name><surname>Balasubramanian</surname><given-names>V</given-names></name><name><surname>Um</surname><given-names>KS</given-names></name><name><surname>Wilson</surname><given-names>T</given-names></name><name><surname>Cillins</surname><given-names>D</given-names></name><name><surname>de Lisle</surname><given-names>G</given-names></name><name><surname>Jacobs</surname><given-names>WR</given-names><suffix>Jr</suffix></name><article-title><italic>inhA</italic>, a gene encoding a target for isoniazid and ethionamide in <italic>Mycobacterium tuberculosis</italic></article-title><source>Science</source><year>1994</year><volume>263</volume><fpage>227</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1126/science.8284673</pub-id><pub-id pub-id-type="pmid">8284673</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Musser</surname><given-names>JM</given-names></name><name><surname>Kapur</surname><given-names>V</given-names></name><name><surname>Williams</surname><given-names>DL</given-names></name><name><surname>Kreiswirth</surname><given-names>BN</given-names></name><name><surname>van Soolingen</surname><given-names>D</given-names></name><name><surname>van Embden</surname><given-names>JD</given-names></name><article-title>Characterization of the catalase-peroxidase gene (<italic>katG</italic>) and <italic>inhA </italic>locus in isoniazid-resistant and -susceptible strains of <italic>Mycobacterium tuberculosis </italic>by automated DNA sequencing: restricted array of mutations associated with drug resistance</article-title><source>J Infect Dis</source><year>1996</year><volume>173</volume><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">8537659</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Basso</surname><given-names>LA</given-names></name><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Musser</surname><given-names>JM</given-names></name><name><surname>Jacobs</surname><given-names>WR</given-names><suffix>Jr</suffix></name><name><surname>Blanchard</surname><given-names>JS</given-names></name><article-title>Mechanisms of isoniazid resistance in <italic>Mycobacterium tuberculosis </italic>: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates</article-title><source>J Infect Dis</source><year>1998</year><volume>178</volume><fpage>769</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">9728546</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Fu</surname><given-names>LM</given-names></name><name><surname>Fu-Liu</surname><given-names>CS</given-names></name><article-title>The gene expression data of <italic>Mycobacterium tuberculosis </italic>based on Affymetrix gene chips provide insight into regulatory and hypothetical genes</article-title><source>BMC Microbiol</source><year>2007</year><volume>14</volume><fpage>7</fpage><lpage>37</lpage></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Karakousis</surname><given-names>PC</given-names></name><name><surname>Yoshimatsu</surname><given-names>T</given-names></name><name><surname>Lamichhane</surname><given-names>G</given-names></name><name><surname>Woolwine</surname><given-names>SC</given-names></name><name><surname>Nuermberger</surname><given-names>EL</given-names></name><name><surname>Grosset</surname><given-names>J</given-names></name><name><surname>Bishai</surname><given-names>WR</given-names></name><article-title>Dormancy phenotype displayed by extracellular <italic>Mycobacterium tuberculosis </italic>within artificial granulomas in mice</article-title><source>J Exp Med</source><year>2004</year><volume>200</volume><fpage>647</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">15353557</pub-id><pub-id pub-id-type="doi">10.1084/jem.20040646</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Korycka-Macha&#x00142;a</surname><given-names>M</given-names></name><name><surname>Rumijowska-Galewicz</surname><given-names>A</given-names></name><name><surname>Dziadek</surname><given-names>J</given-names></name><article-title>The effect of ethambutol on mycobacterial cell wall permeability to hydrophobic compounds</article-title><source>Pol J Microbiol</source><year>2005</year><volume>54</volume><fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">16209089</pub-id></mixed-citation></ref></ref-list></back></article>